Ubiquitination of Immune System and Cancer Therapy

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2024 Nov 15

PMID 39546134

Authors

Yizhou Du

Huiyuan Zhang

Hongbo Hu

Affiliations

Soon will be listed here.

Abstract

Ubiquitination is a post-translational modification mechanism which regulates a variety of signaling pathways and crucial biological processes. It has long been known that ubiquitination regulates the fundamental cellular processes through the induction of proteasomal degradation of target proteins. Meanwhile, the nondegradative types of polyubiquitination modification have been appreciated as important regulatory machinery by modulating the activity or subcellular localization of key signaling proteins. The function of ubiquitination plays an important role in immune responses, which helps to maintain the stability of the internal environment and to control over protein stability and function and are thus critical for the regulation of both innate and adaptive immunity. Furthermore, ubiquitination also regulates both tumor-suppressing and tumor-promoting pathways in cancer. In this review, we will discuss recent progress regarding how ubiquitination regulates immune responses, focusing on Toll-like receptors signaling in innate immunity, T cell activation, TCR signaling, and tumor immunotherapy.

References

Balagopalan L, Coussens N, Sherman E, Samelson L, Sommers C . The LAT story: a tale of cooperativity, coordination, and choreography. Cold Spring Harb Perspect Biol. 2010; 2(8):a005512. PMC: 2908767. DOI: 10.1101/cshperspect.a005512. View

Barton G, Kagan J . A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol. 2009; 9(8):535-42. PMC: 3934928. DOI: 10.1038/nri2587. View

Bastow R, Mylne J, Lister C, Lippman Z, Martienssen R, Dean C . Vernalization requires epigenetic silencing of FLC by histone methylation. Nature. 2004; 427(6970):164-7. DOI: 10.1038/nature02269. View

Beutler B . Innate immunity: an overview. Mol Immunol. 2003; 40(12):845-59. DOI: 10.1016/j.molimm.2003.10.005. View

Bonilla F, Oettgen H . Adaptive immunity. J Allergy Clin Immunol. 2010; 125(2 Suppl 2):S33-40. DOI: 10.1016/j.jaci.2009.09.017. View

Borad A, Ward H . Human immune responses in cryptosporidiosis. Future Microbiol. 2010; 5(3):507-19. PMC: 2856646. DOI: 10.2217/fmb.09.128. View

Brownlie R, Zamoyska R . T cell receptor signalling networks: branched, diversified and bounded. Nat Rev Immunol. 2013; 13(4):257-69. DOI: 10.1038/nri3403. View

Buneeva O, Medvedev A . [Atypical ubiquitination of proteins]. Biomed Khim. 2016; 62(5):496-509. DOI: 10.18097/PBMC20166205496. View

Bushweller J . Targeting transcription factors in cancer - from undruggable to reality. Nat Rev Cancer. 2019; 19(11):611-624. PMC: 8820243. DOI: 10.1038/s41568-019-0196-7. View

10.

Cha J, Yang W, Xia W, Wei Y, Chan L, Lim S . Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018; 71(4):606-620.e7. PMC: 6786495. DOI: 10.1016/j.molcel.2018.07.030. View

11.

Chang M, Jin W, Sun S . Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production. Nat Immunol. 2009; 10(10):1089-95. PMC: 2748822. DOI: 10.1038/ni.1777. View

12.

Chang M, Jin W, Chang J, Xiao Y, Brittain G, Yu J . The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat Immunol. 2011; 12(10):1002-9. PMC: 3178748. DOI: 10.1038/ni.2090. View

13.

Chen Z, Sun L . Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell. 2009; 33(3):275-86. DOI: 10.1016/j.molcel.2009.01.014. View

14.

Chen Z, Chen Y, Peng L, Wang X, Tang N . 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1. J Immunother Cancer. 2020; 8(2). PMC: 7542662. DOI: 10.1136/jitc-2020-001377. View

15.

Courtney A, Lo W, Weiss A . TCR Signaling: Mechanisms of Initiation and Propagation. Trends Biochem Sci. 2017; 43(2):108-123. PMC: 5801066. DOI: 10.1016/j.tibs.2017.11.008. View

16.

Cromm P, Crews C . Targeted Protein Degradation: from Chemical Biology to Drug Discovery. Cell Chem Biol. 2017; 24(9):1181-1190. PMC: 5610075. DOI: 10.1016/j.chembiol.2017.05.024. View

17.

DAmbrosio D, Cantrell D, Frati L, Santoni A, Testi R . Involvement of p21ras activation in T cell CD69 expression. Eur J Immunol. 1994; 24(3):616-20. DOI: 10.1002/eji.1830240319. View

18.

Davis M, Gack M . Ubiquitination in the antiviral immune response. Virology. 2015; 479-480:52-65. PMC: 4774549. DOI: 10.1016/j.virol.2015.02.033. View

19.

Freeman G, Long A, Iwai Y, Bourque K, Chernova T, Nishimura H . Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192(7):1027-34. PMC: 2193311. DOI: 10.1084/jem.192.7.1027. View

20.

Gao H, Sun X, Rao Y . PROTAC Technology: Opportunities and Challenges. ACS Med Chem Lett. 2020; 11(3):237-240. PMC: 7073876. DOI: 10.1021/acsmedchemlett.9b00597. View